N/A N=274 Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial
Circumcision, Male
Primary: Neonatal Salivary Cortisol Level — 0.63; 0.72; 1.14; 1.08 mcg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17,463 Decision Support for Intraoperative Low Blood Pressure
Hypotension
Primary: Postoperative Acute Kidney Injury — 1333; 372; 9670; 2785 Participants
Phase 3 N=46 Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Metastatic Cancer · Pain
Primary: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II) — 39; 37 Participants
Phase 2 N=51 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
N/A N=73 Disposable Stress Urinary Incontinence Pessary Device Study
Stress Urinary Incontinence
Primary: Percentage Reduction of Mean Pad Weight Gain (g/hr) During Treatment Phase as Compared to Baseline Phase. — -47.4 percent change
Phase 2 N=37 Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Objective Response Rate — 10.8 percentage of participants
Phase 2 N=8 Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Parkinson Disease
Primary: Glutathione (GSH) Brain Levels — 0.93; 0.99 mM
Phase 1 N=11 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Phase 2 N=36 Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
Asthma
Primary: Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum Forced Expiratory Volume in 1 Second (FEV1) Between 4-10 Hours Following Allergen Challenge One…
N/A N=411 Study the Impact of the CommunityRx Program on Health, Self-care and Cost
Health Behavior
Primary: Mental Health-related Quality of Life at 3 Months — 50.0; 48.3 score on a scale
N/A N=12 Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness
Dizziness Chronic
Primary: Degrees of Sway — 1.824; 0.746; 1.638; 0.573 degrees of sway — p=0.005
N/A N=60 Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation
Cheek Augmentation · Midface Contour Deficiencies
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety] — 5 Participants
N/A N=18 A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Sickle Cell Disease
Primary: Full Scale IQ (FSIQ) (WASI) — 86.43; 88.0 scores on a scale
N/A N=12 Mobile Device Biomonitoring to Prevent and Treat Obesity in Underserved Youth
Obesity
Primary: Objectively Measured Physical Activity From Accelerometer and KNOWME Network — 1.8 minutes
N/A N=17 VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke
Stroke · Upper Limb Deficits
Primary: Change in Upper Extremity Fugl-Meyer (UEFM) — 7.6; 5.3 units on a scale